{"entity": "journal", "iuid": "cd34f264b2574ab08b898f9a20b176d4", "timestamp": "2026-09-23T21:35:54.228Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/Acta%20Obstet%20Gynecol%20Scand.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/Acta%20Obstet%20Gynecol%20Scand"}}, "title": "Acta Obstet Gynecol Scand", "issn": "1600-0412", "issn-l": null, "publications_count": 2, "publications": [{"entity": "publication", "iuid": "5f649025a922479895e7c9a81b61fe04", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/5f649025a922479895e7c9a81b61fe04.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/5f649025a922479895e7c9a81b61fe04"}}, "title": "Antibiotic use during pregnancy in Sweden: A nationwide utilization study covering 2007-2019.", "authors": [{"family": "Nakitanda", "given": "Aya Olivia", "initials": "AO", "orcid": "0000-0001-7392-208X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/941676155e9c4363b25a4cfb6ed3b014.json"}}, {"family": "Odsbu", "given": "Ingvild", "initials": "I"}, {"family": "Pasternak", "given": "Bj\u00f6rn", "initials": "B"}, {"family": "Karlsson", "given": "P\u00e4r", "initials": "P", "orcid": "0000-0002-7177-1713", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9177884596f74f758d9a3cbfc472a8e0.json"}}, {"family": "Pazzagli", "given": "Laura", "initials": "L"}], "type": "journal article", "published": "2024-03-00", "journal": {"title": "Acta Obstet Gynecol Scand", "issn": "1600-0412", "volume": "103", "issue": "3", "pages": "531-539", "issn-l": null}, "abstract": "Antibiotics are often prescribed during pregnancy. Assessing the current state of prenatal antibiotic use is therefore imperative for optimizing prescribing and identifying emerging research priorities. The study aimed to describe recent trends and patterns in antibiotic use during pregnancy among women who gave birth in Sweden, including user characteristics.\n\nPopulation-based descriptive study using linked nationwide registers. All pregnancies delivered in Sweden from 2007 to 2019 were included. Prevalence of use was defined as the percentage of pregnancies during which at least one prescription forantibiotics was filled. Temporal trends in the prevalence of antibiotic use by calendar year, trimester and weeks of gestation were assessed from time series graphs.\n\nPrescriptions for systemic antibiotics were filled in 20.7% of 1 434 431 pregnancies overall, decreasing from 24.7% in 2007 to 18.0% in 2019. Phenoxymethylpenicillin (8.5%), pivmecillinam (6.5%), nitrofurantoin (4.7%), amoxicillin (1.6%) and cefadroxil (1.5%) use were the most prevalent. Their use decreased over the 13-year period, except for pivmecillinam, which increased from 4.0% to 7.4%. Prevalence of use was highest in the second trimester (9.5%), with weekly trends peaking at 13 and 34 weeks of gestation. Compared with non-users, antibiotic users more often belonged to the youngest and oldest age strata, carried multipleton pregnancies, had delivered before, had attained a lower education level and smoked in early pregnancy. A higher body mass index, asthma, chronic renal disease and diabetes mellitus were more prevalent among antibiotic users than among non-users.\n\nAlthough outpatient antibiotic use during pregnancy in Sweden has been declining, one in five pregnancies was exposed to systemic antibiotics.", "doi": "10.1111/aogs.14741", "pmid": "38108616", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC10867394"}], "notes": [], "created": "2026-09-23T11:25:42.108Z", "modified": "2026-09-23T11:25:42.247Z"}, {"entity": "publication", "iuid": "d413d5d0e7b84b61a960fa93b787591a", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/d413d5d0e7b84b61a960fa93b787591a.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/d413d5d0e7b84b61a960fa93b787591a"}}, "title": "Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia.", "authors": [{"family": "Cesta", "given": "Carolyn E", "initials": "CE", "orcid": "0000-0001-5759-9366", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/35e1b896082549c2b69ead371bf4e3a8.json"}}, {"family": "Segovia Chac\u00f3n", "given": "Silvia", "initials": "S", "orcid": "0000-0003-0210-5829", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/2e63ae649a0e4a18847b5e19d73ea48b.json"}}, {"family": "Engeland", "given": "Anders", "initials": "A", "orcid": "0000-0001-5620-9207", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fa92583833b8407392fef0584366c87e.json"}}, {"family": "Broe", "given": "Anne", "initials": "A", "orcid": "0000-0002-4149-8808", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9ff2659b76694a548fb6a84225f90885.json"}}, {"family": "Damkier", "given": "Per", "initials": "P", "orcid": "0000-0003-0591-7187", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3220b6c562f2497f9122594f270ba2ab.json"}}, {"family": "Furu", "given": "Kari", "initials": "K", "orcid": "0000-0003-2245-0179", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f00c9192b2a642869c13e93ca5526147.json"}}, {"family": "Kieler", "given": "Helle", "initials": "H", "orcid": "0000-0001-9338-7133", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/831da95a6b2f4a9b9e29aed574219101.json"}}, {"family": "Karlsson", "given": "P\u00e4r", "initials": "P", "orcid": "0000-0002-7177-1713", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9177884596f74f758d9a3cbfc472a8e0.json"}}], "type": "journal article", "published": "2021-11-00", "journal": {"title": "Acta Obstet Gynecol Scand", "issn": "1600-0412", "volume": "100", "issue": "11", "pages": "2111-2118", "issn-l": null}, "abstract": "For phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, the only approved indication in women is for pulmonary arterial hypertension. These drugs are increasingly being proposed and tested for treatment of female infertility and complications in pregnancy. However, the extent of use of PDE5 inhibitors in the general pregnant population over the last decades is unknown. Therefore, we conducted a descriptive cohort study using data from the population health registers in the Scandinavian countries.\n\nBy linking the Medical Birth Registers and the Prescribed Drug Registers in Denmark (1997-2017), Norway (2004-2017), and Sweden (2006-2016), women with filled prescriptions of PDE5 inhibitors in outpatient settings in the 90 days before the date of last menstrual period and/or during pregnancies were identified. With additional linkage to the National Patient Registers, information on maternal, pregnancy, and infant characteristics, co-morbidities, and co-medication was collected and described.\n\nAmong over 3 million singleton pregnancies, only 77 were pregnancies in women who had at least one filled prescription of a PDE5 inhibitor within the 90 days before the start of pregnancy to delivery. Prescription fills most often occurred before the last menstrual period and in the first trimester, with very few occurring later in pregnancy. Sildenafil was the most used PDE5 inhibitor. Among pregnant women using PDE5 inhibitors, 44% were 35 years of age or older, eight had a cardiovascular diagnosis, and three specifically had a diagnosis of pulmonary arterial hypertension. Among the infants born to mothers using PDE5 inhibitors, nine were born preterm, six were small-for-gestational age, five had an Apgar score at 5 minutes below 8, 18 were admitted to the Neonatal Intensive Care Unit, and eight had respiratory and cardiovascular conditions.\n\nFew women used PDE5 inhibitors in outpatient settings before or during pregnancy in the Scandinavian countries in the last decades. Only a small proportion had a diagnosis for pulmonary arterial hypertension, suggesting off-label use in the remaining users. Use was predominantly in mothers over age 35 years. The safety of fetal exposure to sildenafil and other PDE5 inhibitors in pregnancy has not been established. As maternal age continues to increase and additional uses of PDE5 inhibitors are investigated, the safety of these drugs in pregnancy should be thoroughly evaluated.", "doi": "10.1111/aogs.14251", "pmid": "34453753", "labels": [], "xrefs": [], "notes": [], "created": "2026-09-23T13:11:17.932Z", "modified": "2026-09-23T13:11:18.147Z"}], "created": "2026-09-23T11:25:42.212Z", "modified": "2026-09-23T11:25:42.212Z"}